Theresa Kavanaugh is a senior partner in the firm’s nationally recognized Life Sciences group. Ms. Kavanaugh has been consistently recognized as a leading life science patent attorney, including selection for yearly inclusion since 2013 in U.S. News-Best Lawyers and selection as an LMG Life Science star. Her practice focuses on developing and implementing complex patent and market exclusivity strategies with a focus on chemical and biologic therapeutics. Her practice includes patent portfolio management in anticipation of product approval, company partnering, M&A, and financing events, including public offerings.





Dr. Kavanaugh has significant experience in developing patent strategies throughout the developmental life cycle of chemical and biologic therapeutics.  She has shepherded patent strategies from early stage patent development for discovery programs through post approval patent strategy for FDA-approved therapeutics and then successfully through post grant and litigation challenge. Her strategic patent counseling, which has helped her clients achieve significant funding from acquisitions, public market offerings and private investments, includes patentability, freedom to operate analyses, FDA Orange Book listing strategy and ANDA preparation for small molecules, biosimilar strategy for biologics, patent term extension strategy, and preparing for and conducting post grant patent review procedures, including Inter Partes Review (IPR) proceedings at the USPTO. She has extensive technical expertise with pharmaceutical and small molecule therapeutics; protein, antisense and other biologic therapies; diagnostic and drug discovery platform technologies, microbiome modulator technology; polymer chemistry; drug delivery and extended release formulations; materials science; and chemical process technologies. Clients also benefit from her experience on IP matters as part of initial public offerings and venture investments.

Representative Matters



Patent Counseling
  • Aptinyx on patent matters relating to NMDA small molecule modulators, including patent matters leading to its $65 million Series A financing, and its recent IPO.
  • Assembly Biosciences on patent matters relating to its HBV and microbiome programs and its $69 million public follow-on offering
  • Zafgen Inc. on patent portfolio strategy and patent matters relating to its MetAP-2 inhibitor small molecule program and its $96 million public offering and subsequent $137 million follow-on public offering
  • Nogra Pharma Ltd. (Ireland) on patent portfolio strategy and patent matters relating to small molecule therapeutics including PPARg modulators; IL-34 technology; and SMAD7 antisense therapy.
  • AMAG Pharmaceuticals on patent matters relating to its marketed products, including Feraheme®, and its $201 million follow-on and $225 convertible note offerings
  • Aegerion Pharmaceuticals on patent matters relating to the approved small molecule lomitapide and BLA approved product metreleptin; including representing the licensor/patent owner in an inter partes review involving patents directed to a novel dosing regimen for lomitapide, with Final Written Decisions upholding the validity of the patents (Coalition for Affordable Drugs VIII, LLC v. The Trustees of the University of Pennsylvania)
  • Neuroderm Ltd. (Israel) on patent matters relating to its CNS small molecule therapeutics, its U.S. IPO and later acquisition by Mitsubishi Tanabe Pharma Company for an equity value of approximately $1.1 billion
  • Proteostasis Therapeutics on patent prosecution matters and strategy relating to its cystic fibrosis transmembrane regulator small molecule program, including patent matters leading to its $50 million initial public offering and $65 million  and $40 million follow-on public offerings
  • Full life cycle patent strategy on behalf of a pharmaceutical company with a recently approved orphan drug
  • Early stage platform and discovery stage patent strategies for several pharmaceutical and biological therapeutic companies
  • Post grant review challenges on patents relating to approved products
  • Preparation of the published patent application that includes the CAS Registry 100 millionth substance, (4S)-6-(4-chlorophenyl)-N-ethyl-8-[2-[[4[hydroxydimethylsilyl)-methyl]benzoyl]amino]ethoxy]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide
Patent Due Diligence/M&A
  • BridgeBio Pharma, for its new subsidiary, QED Therapeutics
  • Nogra Pharma Ltd. (Ireland) on patent portfolio strategy and patent matters relating to its agreement with Celgene Corporation for an oral, SMAD7 antisense therapy for Crohn’s disease; the agreement includes one of the largest upfront payments for a licensing deal in the last 10 years
  • Aegerion Pharmaceuticals on patent matters leading to its merger with Novelion (QLT)
  • Naurex Inc. on patent portfolio development and patent matters relating to its NMDA small molecule and peptidyl programs and in connection with its recent $560 million merger with Allergan PLC
  • BIND Therapeutics on patent matters relating to its nanomedicine platform, its initial public offering on the NASDAQ Stock Market and its subsequent acquisition by Pfizer
Professional Activities

Dr. Kavanaugh is a member of the American Intellectual Property Law Association, the Boston Patent Law Association and the American Chemical Society.

In The News









J.D., 2005
Northeastern University School of Law
Ph.D., Chemistry, 1992
Massachusetts Institute of Technology
M.L.I.S., 1997
Simmons College
M.S., Chemistry, 1987
The University of Texas at Austin
B.S., Chemistry, 1986
University of California



U.S. Patent and Trademark Office (USPTO)
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique